He pioneered computational biology for cancer. Why is the lab going silent now?

Also: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment

December 9, 2025 Check out STAT+

Sponsored By

Sophie Park for STAT His lab was humming with discovery. After one year under Trump, it's almost silent Computational biology pioneer John Quackenbush watched a lab once humming with discovery go silent. Part 4 of STAT's "American Science, Shattered" series. By Angus Chen STAT+ | New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment At the American Society of Hematology annual meeting, Gilead and Arcellx reported promising data for their multiple myeloma CAR-T therapy anito-cel. By Adam Feuerstein STAT+ | Cancer detection firm Freenome to go public via $330 million SPAC deal Freenome will hit the public markets by merging with Perceptive Capital Solutions Corp, a SPAC, in a $330 million deal. By Jonathan Wosen CNRI/SCIENCE PHOTO LIBRARY STAT+ | Incyte study results suggest a new approach to treating myelofibrosis The data bolster Incyte's efforts to develop a new type of drug for myelofibrosis, and suggest the treatment may help it replace Jakafi. By Adam Feuerstein

More around STAT

---

In case you missed it What West Virginia teens lost when CDC cuts ended their fight against Big Tobacco, STAT After NIH grant cuts, breast cancer research at Harvard slowed, and lab workers left, NPR Why some doctors say there are cancers that shouldn't be treated, New York Times

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser